1. Home
  2. MTLS vs DMAC Comparison

MTLS vs DMAC Comparison

Compare MTLS & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MTLS
  • DMAC
  • Stock Information
  • Founded
  • MTLS 1990
  • DMAC 2000
  • Country
  • MTLS Belgium
  • DMAC United States
  • Employees
  • MTLS N/A
  • DMAC N/A
  • Industry
  • MTLS Computer Software: Prepackaged Software
  • DMAC Biotechnology: Pharmaceutical Preparations
  • Sector
  • MTLS Technology
  • DMAC Health Care
  • Exchange
  • MTLS Nasdaq
  • DMAC Nasdaq
  • Market Cap
  • MTLS 316.0M
  • DMAC 178.0M
  • IPO Year
  • MTLS 2014
  • DMAC N/A
  • Fundamental
  • Price
  • MTLS $5.74
  • DMAC $3.76
  • Analyst Decision
  • MTLS
  • DMAC Strong Buy
  • Analyst Count
  • MTLS 0
  • DMAC 2
  • Target Price
  • MTLS N/A
  • DMAC $8.00
  • AVG Volume (30 Days)
  • MTLS 88.3K
  • DMAC 307.4K
  • Earning Date
  • MTLS 07-30-2025
  • DMAC 08-06-2025
  • Dividend Yield
  • MTLS N/A
  • DMAC N/A
  • EPS Growth
  • MTLS 43.31
  • DMAC N/A
  • EPS
  • MTLS 0.17
  • DMAC N/A
  • Revenue
  • MTLS $291,295,936.00
  • DMAC N/A
  • Revenue This Year
  • MTLS $6.42
  • DMAC N/A
  • Revenue Next Year
  • MTLS $8.33
  • DMAC N/A
  • P/E Ratio
  • MTLS $33.69
  • DMAC N/A
  • Revenue Growth
  • MTLS 6.16
  • DMAC N/A
  • 52 Week Low
  • MTLS $3.93
  • DMAC $2.80
  • 52 Week High
  • MTLS $9.69
  • DMAC $6.82
  • Technical
  • Relative Strength Index (RSI)
  • MTLS 59.22
  • DMAC 47.18
  • Support Level
  • MTLS $5.52
  • DMAC $3.48
  • Resistance Level
  • MTLS $5.82
  • DMAC $3.99
  • Average True Range (ATR)
  • MTLS 0.17
  • DMAC 0.32
  • MACD
  • MTLS 0.00
  • DMAC -0.00
  • Stochastic Oscillator
  • MTLS 81.67
  • DMAC 41.01

About MTLS Materialise NV

Materialise NV is a provider of 3D printing services. The products and services of the group are organized in three segments: Medical segment, which develops and delivers medical software solutions, medical devices, and other related products and services; Software segment, which develops and delivers additive manufacturing software solutions and related services; and Manufacturing segment, which delivers 3D printed products and related services. Its geographical segments are the United States, the Americas (excluding the USA), Belgium, Germany, France, Switzerland, the United Kingdom, Italy, the Netherlands, Other Europe, and the Asia Pacific.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: